Unnamed Pharmaceuticals: Explanation and Verification Opinions of the Supervisory Board on the Publication of the Company\'s 2024 Stock Option Incentive Plan Incentive List
Unnamed Pharmaceuticals: Announcement on the progress of the transfer of shares in participating companies through public listing
Unnamed Pharmaceuticals: Announcement on the Change of Chief Financial Officer
Unnamed Medicine: Announcement of Resolutions of the 30th Meeting of the Fifth Board of Directors
Unnamed Pharmaceuticals: An indicative announcement on the adoption of an autonomous exercise model during the first exercise period of the 2023 Stock Options Incentive Plan
Unnamed Pharmaceuticals: Shandong Weiming Biomedical Co., Ltd. 2024 Stock Option Incentive Plan Implementation Assessment Measures
Unnamed Pharmaceutical: Notice on requesting the shareholders\' meeting to authorize the board of directors to handle matters relating to the company\'s 2024 stock option incentive plan
Unnamed Medicine: Announcement on the By-election of Independent Directors of the 5th Board of Directors and the Adjustment of Members of the Special Committee of the Board
Unnamed Medicine: Announcement of Resolutions of the 20th Meeting of the Fifth Board of Supervisors
Unnamed Medicine: 2024-069 Announcement of Resolutions of the 29th Meeting of the Fifth Board of Directors
Unnamed Medicine: Legal Opinion of Zhejiang Tianzu (Shenzhen) Law Firm on Shandong Weiming Biomedical Co., Ltd. 2024 Stock Option Incentive Plan (Draft)
Unnamed Pharmaceuticals: Supervisory Board\'s Review Opinions on Matters Related to the 2024 Stock Options Incentive Plan
Unnamed Pharmaceuticals: Independent Director Candidate Statements and Commitments - Cai Yanhong
Unnamed Pharmaceuticals: Draft Equity Incentive Plan Self-Inspection Form
Unnamed Pharmaceuticals: Shandong Weiming Biomedical Co., Ltd. 2024 Stock Option Incentive Plan Draft (Summary)
Unnamed Pharmaceuticals: Independent Director Nominee\'s Statement and Commitment - Cai Yanhong
Unnamed Pharmaceuticals: Notice on Convening the Fourth Extraordinary General Meeting of Shareholders in 2024
Unnamed Medicine: Independent Directors\' Open Call for Delegated Voting Rights Report
Weiming Pharmaceutical: Shandong Weiming Biomedical Co., Ltd. 2024 Stock Option Incentive Plan (Draft)
Unnamed Pharmaceuticals: 2024 Stock Option Incentive Plan Incentive List
No Data